NCT03762603 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Goto K, Morishita T, Kamada S, Saita K, Fukuda H, Shiota E, Sankai Y, Inoue T
Feasibility of rehabilitation using the single-joint hybrid assistive limb to facilitate early recovery following total knee arthroplasty: A pilot study. Assist Technol. 2017 W
Healy WL, Rana AJ, Iorio R
Hospital economics of primary total knee arthroplasty at a teaching hospital. Clin Orthop Relat Res. 2011 Jan;469(1):87-94. doi: 10.1007/s11999-010-1486-2.
Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M
Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am. 2005 Jul;87(7):1487-97.
Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, Wright EA, Holt HL, Solomon DH, Yelin E, Paltiel AD, Katz JN
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med. 2009 Jun 22;16
Schwarzkopf R, Ho J, Quinn JR, Snir N, Mukamel D
Factors Influencing Discharge Destination After Total Knee Arthroplasty: A Database Analysis. Geriatr Orthop Surg Rehabil. 2016 Jun;7(2):95-9. doi: 10.1177/2151458516645635. Epub 2016 Apr 26.

Does Supplementing of Quadriceps Strength With Exoskeleton After Total Knee Arthroplasty in High Risk Population Reduce Transfer to Extended Care Facility (ECF)

Details for clinical trial NCT03762603

Clinical trial NCT03762603 - References